Trial Search Results

Gastrointestinal STRING Test With Oral Immunotherapy

This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST). The primary objective is to determine the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation in the esophagus of subjects treated with omalizumab-facilitated mOIT(mult-allergen oral immunotherapy) and/or mOIT with concurrent dupilumab.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Device: Entero-tracker

Eligibility


Inclusion Criteria: • Participants, aged 5-55 years enrolled in the parent COMBINE trial

   - Able to swallow the EST.

Exclusion Criteria: • Allergy to, or inability to ingest, gelatin

-

Ages Eligible for Study

5 Years - 55 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305